10 Common Mistakes to Avoid When Prescribing SGLT2 Inhibitors and GLP-1 Drugs

Managing heart and metabolic health has changed quickly. Today, two types of medicine, SGLT2 inhibitors and GLP-1 receptor agonists, are the main tools for treating type 2 diabetes, obesity, and heart risks. You likely know them by brand names like Ozempic, Wegovy, and Mounjaro.

Because these drugs work so well, doctors are prescribing them more than ever. However, making small mistakes during the process can hurt the patient’s progress. It is vital to catch these errors before they lead to real harm.

Common Errors and How to Fix Them

Mistake 1: Not Checking Kidney Function First

You must check a patient’s kidney health before starting an SGLT2 inhibitor. These drugs need the kidneys to work well enough to move sugar out of the body. If the kidney filtration rate (eGFR) is too low, the drug will not help control blood sugar.

In light of this, doctors should check these levels at the start. You must also monitor them regularly as time goes on. This is especially true for patients who already have kidney disease.

Mistake 2: Missing the Signs of “Hidden” Ketoacidosis

SGLT2 inhibitors can cause a rare but scary issue called euglycemic DKA. In this case, the patient has acid in their blood, but their blood sugar looks normal. This “normal” number can trick doctors into thinking everything is fine.

Things like fasting, surgery, or very low-carb diets can trigger this. Therefore, patients should stop taking the drug three days before a scheduled surgery. They must also know to call a doctor if they feel sick or weak.

Mistake 3: Forgetting to Lower Other Insulin Doses

Both GLP-1 and SGLT2 drugs are powerful at lowering blood sugar. If a patient is already taking insulin or pills like glipizide, adding these new drugs can make their sugar drop too low. This leads to dangerous hypoglycemia.

To be precise, you should often lower the old medication doses right away. Building on this, always give the patient a clear plan for changing their doses. Preventing a “sugar crash” is a top priority.

Mistake 4: Missing Important Health Warnings

GLP-1 drugs come with a “boxed warning” about certain thyroid tumors. Because of this, you cannot give them to anyone with a family history of medullary thyroid cancer. You must also ask about any past issues with the pancreas.

Given this, a full medical history is not optional. You must rule out these risks before the first dose. Safety always comes before weight loss or sugar control.

Mistake 5: Stopping at Too Low a Dose

Many people feel nauseous or have an upset stomach when they start GLP-1 drugs. Some doctors react by keeping the patient on a tiny “starter” dose forever. Unfortunately, these low doses do not provide the full health benefits.

Most patients feel better if they follow a slow, steady schedule to raise the dose. Along with this, teaching patients to eat smaller meals can help. Reaching the target dose is the only way to get the best results.

Mistake 6: Blaming All Bladder Issues on the Drug

SGLT2 inhibitors put more sugar in the urine, which can cause yeast infections. However, doctors sometimes blame the drug for every bladder symptom and stop the treatment too soon. This can be a mistake.

Meanwhile, doctors might miss a much more serious skin infection called Fournier’s gangrene. While very rare, it is a surgical emergency. Always do a physical exam rather than just guessing.

Mistake 7: Treating All Drugs the Same

Even though these drugs are in the same groups, they do different things. SGLT2 inhibitors are amazing at keeping people out of the hospital for heart failure. GLP-1 drugs are often better at preventing strokes or heart attacks.

Accordingly, you should pick the drug based on the patient’s specific heart risk. Do not treat them as if they are the same thing. Matching the right drug to the right person is key.

Mistake 8: Forgetting About Water Weight and Blood Pressure

SGLT2 inhibitors act like a mild “water pill.” If a patient already takes a diuretic, they might lose too much fluid. This can lead to dizziness, low blood pressure, or even fainting.

In view of this, you might need to lower their other blood pressure meds. Monitor their hydration and blood pressure closely in the first few weeks. This is very important for older patients.

Mistake 9: Not Talking About Realistic Weight Loss

Patients often see “miracle” stories on the news about weight loss drugs. They might feel like failures if they only lose a little bit at first. If they get discouraged, they might quit too soon.

Hence, you must explain that weight loss takes time. It is a slow, steady process that needs a healthy diet to work. Setting honest goals from day one helps patients stay on track.

Mistake 10: Stopping the Meds Without a Backup Plan

If a patient suddenly stops a GLP-1 drug, the weight and high blood sugar usually come back fast. These are often meant to be long-term “chronic” treatments. They are not a quick fix that you can just turn off.

Therefore, you must have a plan if a patient needs to stop. Never just cut the medicine off without a transition. Keeping the heart and kidneys protected is a lifelong job.

Conclusion

Using these new tools requires more than just writing a script. It takes careful attention to the patient’s history and constant check-ups. When used correctly, these drugs can truly save lives and prevent heart attacks.

By avoiding these ten mistakes, you can help your patients get the most out of their treatment. Good medicine is about the details. Following these steps ensures your patients stay safe while they get healthy.

References

American Diabetes Association Professional Practice Committee for Diabetes. (2026). 11. Chronic kidney disease and risk management: Standards of Care in Diabetes 2026. Diabetes Care, 49(Supplement_1), S246–S260. https://doi.org/10.2337/dc26-S011

de Boer, I. H., Khunti, K., Sadusky, T., Tuttle, K. R., Neumiller, J. J., Rhee, C. M., Rosas, S. E., Rossing, P., Bakris, G., & Molitch, M. E. (2022). Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care, 45(12), 3075–3090. https://doi.org/10.2337/dci22-0027 

Novo Nordisk. (n.d.). Oral GLP-1 receptor agonist: RYBELSUS® (semaglutide) tablets 7 mg or 14 mg. NovoMedLink. Retrieved May 30, 2026, from https://www.novomedlink.com/diabetes/products/treatments/rybelsus/about.html